PubMed
Semax and its derivatives: neuroprotective peptides (review)
Ashmarin IP, Nezavibatko VN. Neurosci Behav Physiol. 2018
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 62% · Mixed 28% · Unfavorable overall 10%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg
Reports span 0.1–2 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 57% said they felt similar to their last entry, 36% more positive, and 12% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 31 days · Based on 484 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 60% · Mixed 32% · Unfavorable overall 8%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 100–200 mcg · Most common: 100–200 mcg
Reports span 0–1000 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 55% said they felt similar to their last entry, 34% more positive, and 20% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 14 days · Based on 312 repeat reporters
Published sources linked on the Adamax and CBL-514 wiki pages.
PubMed
Ashmarin IP, Nezavibatko VN. Neurosci Behav Physiol. 2018
PubMed
Dmitrieva VG, Povarova OV, Skvortsova VI, et al. Mol Genet Genomics. 2013
PubMed
Gold M, Schlessinger J, Goodman GJ, et al. Aesthetic Surgery Journal. 2025
PubMed
Lorenc ZP, Gold M, Schlessinger J, et al. Aesthetic Surgery Journal. 2026
PubMed
Goodman GJ, Ho WWS, Chang KJ, et al. Aesthetic Surgery Journal. 2022
PubMed
Herbst KL, Ling YF, Sheu AY, et al. JAAD International. 2026
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2026
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2026
Manufacturer
Caliway Biopharmaceuticals. Company press release. 2026
Manufacturer
Caliway Biopharmaceuticals. Company press release. 2026
Manufacturer
Caliway Biopharmaceuticals. Company press release. 2026
FDA Drug Label
Allergan. FDA Drug Label. 2015
Review Article
Tina Hesman Saey, Science News. Science News. 2026
Review Article
News-Medical.net. Conference news summary. 2026